Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release -"Wockhardt's Zaynich® (Zidebactam/Cefepime) Receives Favourable Recommendation from CDSCO's Subject Expert Committee for Treatment of Gram-Negative Infections".
Press Release Mar 30 2026
Filed with NSE · · 3 pages · English
Release
Earlier from Wockhardt
- Press Release Feb 10 2026
- Press Release Jan 27 2026
- Press Release Jan 07 2026
- Press Release Dec 31 2025
- Press Release Dec 01 2025
Later from Wockhardt
- Press Release May 04 2026
- Press Release May 28 2026
- Press Release May 30 2026
- Wockhardt Receives U.S. FDA Approval for ZAYNICH™ (cefepime and zidebactam), a Novel Intravenous Antibiotic for the Treatment of Adult Patients with Complicated Urinary Tract Infection Including Pyelonephritis
- Wockhardt Limited Press Release Aug 10 2026
Follow Wockhardt into a list and get an email when it puts out news.
Follow Wockhardt